Fairvalue-Calculator Fairvalue-Calculator
EN DE

Shandong Sito Bio-technology Co (300583) Fair Value & Analysis

Healthcare · CN · Market cap 2.2B CNY

Price¥11.58
Fair Value¥13.22
Upside+14.2%
Quality93/100
Evidence: High Range ¥7.20 – ¥28.22

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Shandong Sito Bio-technology Co (300583) currently trades at ¥11.58, while our model-based Fair Value estimate is ¥13.22 — implying the stock looks roughly 14.2% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-dione and estra-4,9-diene-3,17-dione. Shandong Sito Bio-technology Co., Ltd. was founded in 2002 and is based in Heze, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Shandong Sito Bio-technology Co (300583) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥13.22 versus a price of ¥11.58 — about +14% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 300583?
Our 21-model fair value for Shandong Sito Bio-technology Co is ¥13.22 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥11.58.
What is the quality score of 300583?
Shandong Sito Bio-technology Co has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.